Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15561902 | 0.97 | TSHR (0.47) | TSHRPOLBHTR3ADRD2GRM2 | |
| SCHEMBL3781520 | 0.88 | TSHR (0.37) | TSHRHTR3AALDH1A1ESR2SLC6A2 | |
| SCHEMBL3787031 | 0.88 | SLC6A2 (0.38) | TSHRHTR3ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3786509 | 0.86 | CYP11B2 (0.39) | TSHRHTR3AALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL15562086 | 0.86 | TSHR (0.42) | TSHRHTR3AALDH1A1GRM2ESR2 | |
| SCHEMBL3792058 | 0.85 | CYP3A4 (0.52) | TSHRALDH1A1GRM2TP53CYP3A4 | |
| SCHEMBL14336873 | 0.85 | ESR2 (0.48) | TSHRDRD2GRM2ESR2ADAMTS5 | |
| SCHEMBL22815882 | 0.85 | ESR2 (0.48) | TSHRDRD2GRM2ESR2ADAMTS5 | |
| SCHEMBL22815878 | 0.85 | TSHR (0.36) | TSHRGRM2ADAMTS5 | |
| SCHEMBL3235797 | 0.85 | WDR5 (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121393-A | Aromatic amide compound and application thereof in medicines | 广东东阳光药业有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-113121463-A | Amide compound with bicyclic structure and application thereof in medicines | 广东东阳光药业有限公司 | 2021-07-16 | — | — | CN | disclosed |
| WO-2021136326-A1 | ARYL AMIDE COMPOUND AND APPLICATION THEREOF IN MEDICINE | 广东东阳光药业有限公司 | 2021-07-08 | — | — | WO | disclosed |
| WO-2021136339-A1 | AMIDE COMPOUND WITH BICYCLIC STRUCTURE AND USE THEREOF IN DRUG | 广东东阳光药业有限公司 | 2021-07-08 | — | — | WO | disclosed |
| EP-2307394-B1 | SULPHONAMIDES AS VANILLOID RECEPTOR ANTAGONIST | AMOREPACIFIC CORP (KR) | 2012-09-26 | — | — | EP | disclosed |
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
| EP-2307394-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2011-04-13 | — | — | EP | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| WO-2010002209-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2010-01-07 | — | — | WO | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | TSHR 2249/4885POLB 4833/4885HTR3A 202/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | TSHR 1688/4885POLB 2303/4885HTR3A 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.